The IPO received bids for 281.45 crore shares against 4.4 crore shares on offer.
The Qualified Institutional Buyers (QIBs) booked their quota 182.65 times, while the Non-institutional investors (NIIs) subscribed their portion 42.36 times. The retail quota was booked 5.64 times. The employees’ category was booked 6.6 times.The IPO price band was fixed between ₹540 and ₹570 per share.
Following the IPO share allotment, the company will initiate refunds and transfer of shares to the Demat accounts on July 18.
Shares of Anthem Biosciences Ltd. are expected to debut on both the BSE and NSE on Monday, July 21.
The IPO investors can check the share allotment status on the websites of the BSE, NSE and the issue registrar, Kfin Technologies.
How to check IPO allotment status online
Steps to check share allotment status on BSE
· Go to the BSE IPO allotment page: https://www.bseindia.com/investors/appli_check.aspx
· Select ‘Equity’ as the issue type.
· Choose ‘Anthem Biosciences’ from the dropdown menu.· Enter your PAN or application number.
· Click on ‘Search’ to view your allotment status.
Steps to check share allotment status on Kfin Technologies’ website
· Visit the IPO allotment status page on Kfin Technologies’ website: https://ris.kfintech.com/ipostatus/
· Select any of the ‘Links’ out of the five options.
· Select ‘Anthem Biosciences’ from the dropdown.
· Enter your PAN, application number, or DP/Client ID.
· Click ‘Submit’ to check your status.
Anthem Biosciences IPO allotment status can also be checked on the NSE website using the application number and PAN.
About Anthem Biosciences
The IPO was only an Offer-for-Sale (OFS) by existing shareholders, including investors Viridity Tone and Portsmouth Technologies. As it was a complete OFS, the company will not receive any proceeds from the issue; all funds will go to the selling shareholders.
Founded in 2006, Anthem Biosciences is a full-service Contract Research, Development and Manufacturing Organisation (CRDMO). The company provides end-to-end solutions to pharmaceutical and biotech companies, spanning from early-stage research to commercial-scale manufacturing, offering an integrated model that streamlines operations and ensures regulatory compliance.
